Abstract:BACKGROUND.: We have shown that high-dose intravenous immune globulin (IVIG; 2 g/kg x2 doses)+rituximab (1 g x2 doses) was effective in lowering anti-human leukocyte antigen (HLA) antibodies and improving rates of transplantation. The aim of this report was to evaluate the efficacy of IVIG+rituximab on reduction of anti-HLA antibodies to a level that was permissive for living donor (LD) or deceased donor (DD) transplantation without incurring the risk of antibody-mediated rejection and immediate graft loss. ME… Show more
“…Some authors have reported good outcomes using rituximab, PEX, and IVIG, which are effective in the treatment of rejection in immunologically high-risk patients. [11][12][13][14][15] These 3 methods were designed to inhibit existing antibodies. Rituximab is a chimeric anti-CD20 (anti-B cell) monoclonal antibody approved for the treatment of lymphoma.…”
Section: Discussionmentioning
confidence: 99%
“…Good outcomes using rituximab, plasma exchange (PEX), and intravenous immunoglobulin (IVIG) have been reported in immunologically high-risk patients. [11][12][13][14][15] We achieved better outcomes using a unique protocol that combined these methods including the use of retuximub, PEX, and IVIG in patients who were FCXM-positive for both T and B cells (FCXM T+B+). In the present study, we investigated the clinical course of FCXM T+B+ patients to validate our strategy.…”
“…Some authors have reported good outcomes using rituximab, PEX, and IVIG, which are effective in the treatment of rejection in immunologically high-risk patients. [11][12][13][14][15] These 3 methods were designed to inhibit existing antibodies. Rituximab is a chimeric anti-CD20 (anti-B cell) monoclonal antibody approved for the treatment of lymphoma.…”
Section: Discussionmentioning
confidence: 99%
“…Good outcomes using rituximab, plasma exchange (PEX), and intravenous immunoglobulin (IVIG) have been reported in immunologically high-risk patients. [11][12][13][14][15] We achieved better outcomes using a unique protocol that combined these methods including the use of retuximub, PEX, and IVIG in patients who were FCXM-positive for both T and B cells (FCXM T+B+). In the present study, we investigated the clinical course of FCXM T+B+ patients to validate our strategy.…”
“…In these studies rejection rates were 31-59% and patient and graft survival was 96-100% and 75-100% respectively. Four of the studies included rituximab as a part of their pre-transplant conditioning regimens [62][63][64][65]. Despite the addition of rituximab, AMR rates remained high, 37-50% and patient and graft survival were similar to the IVIG alone groups 86-100% and 79-94% respectively.…”
Section: Modulation Of the Immune Response In Recipients With Crossmamentioning
“…In this cohort, desensitized patients waited for an additional 4.2±4.5 months before receiving a deceased donor graft. Overall graft failure and death at 2 years were 80% and 91% respectively, but almost 30% of graft loss was directly attributed to AMR (Vo, Peng et al 2010). …”
Section: Desensitization Of Highly-sensitized Patients On Deceased Domentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.